Methylcholanthrene


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D000236 Adenoma PMID:10545420; PMID:6695378
MESH:D001161 Arteriosclerosis PMID:3142695
MESH:D001749 Urinary Bladder Neoplasms PMID:7231638
MESH:D001943 Breast Neoplasms PMID:17474063
MESH:D002277 Carcinoma PMID:10545420; PMID:21163286
MESH:D002294 Carcinoma, Squamous Cell PMID:12015029; PMID:3359417
MESH:D002471 Cell Transformation, Neoplastic PMID:11690565; PMID:11808923; PMID:16192471; PMID:39109301; PMID:6302407; PMID:9703276
MESH:D002779 Cholestasis PMID:1283232
MESH:D002869 Chromosome Aberrations PMID:31712135
MESH:D004195 Disease Models, Animal PMID:17971093
MESH:D004487 Edema PMID:19043309
MESH:D005354 Fibrosarcoma PMID:10626785; PMID:10962813; PMID:12549624; PMID:14633661; PMID:23548910
MESH:D006501 Hepatic Encephalopathy PMID:12175977; PMID:17971093
MESH:D006965 Hyperplasia PMID:117197
MESH:D008114 Liver Neoplasms, Experimental PMID:117197; PMID:1399818; PMID:9140468
MESH:D008175 Lung Neoplasms PMID:10545420; PMID:11195466; PMID:11893704; PMID:12015029; PMID:1399818; PMID:15390079; PMID:16271038; PMID:16337739; PMID:17909032; PMID:20101149; PMID:20512841; PMID:20970405; PMID:21163286; PMID:32726451; PMID:6695378; PMID:6927645; PMID:7750092; PMID:9230183
MESH:D008679 Metaplasia PMID:21163286
MESH:D009369 Neoplasms PMID:1934296
MESH:D009374 Neoplasms, Experimental PMID:32726451; PMID:36807623; PMID:679184
MESH:D011230 Precancerous Conditions PMID:117197; PMID:3167864
MESH:D011297 Prenatal Exposure Delayed Effects PMID:11195466; PMID:6927645
MESH:D014625 Vaginal Neoplasms PMID:3359417
MESH:D017114 Liver Failure, Acute PMID:17971093
MESH:D019954 Neurobehavioral Manifestations PMID:17971093
MESH:D048629 Micronuclei, Chromosome-Defective PMID:27163632; PMID:3764927; PMID:6424008; PMID:6472309
MESH:D050197 Atherosclerosis PMID:11922910
MESH:D064420 Drug-Related Side Effects and Adverse Reactions PMID:9023573

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.